Neutrophil-to-Lymphocyte Ratio as a Prognostic Marker in Chronic Obstructive Pulmonary Disease: Assessing Exacerbations, Mortality, and Systemic Inflammation

Lionel John J ¹, Srinivasan N ¹, Shiva P ^1*, Radhakrishnan P ¹

The NLR is a promising, cost-effective marker for predicting COPD exacerbations and mortality, with potential for routine clinical use.

Abstract

Background: Chronic Obstructive Pulmonary Disease (COPD) is a progressive condition characterized by inflammation and destruction of pulmonary tissue, leading to chronic airflow limitation. In addition to pulmonary complications, COPD is frequently associated with systemic inflammation and various comorbidities, which contribute to increased morbidity and mortality. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential marker of systemic inflammation and disease severity in COPD. Methods: This review synthesizes findings from studies evaluating NLR in COPD patients, including those with stable disease, acute exacerbations (AECOPD), and various comorbid conditions. We examined studies that investigated the role of NLR in predicting disease severity, exacerbation risk, and mortality, and explored its relationship with traditional inflammatory markers and comorbidities. Results: NLR values are significantly higher in COPD patients compared to healthy controls and show strong correlations with other inflammatory markers such as C-reactive protein (CRP) and red cell distribution width (RDW). Elevated NLR is associated with increased risk of AECOPD, bacterial infections, and mortality. Specific NLR cut-off values have been identified for different clinical scenarios, with higher values indicating greater disease severity and worse outcomes. Studies also highlight the influence of comorbid conditions, such as metabolic syndrome and cancer, on NLR levels. Conclusion: NLR is a simple, cost-effective marker with potential utility in assessing disease severity, exacerbation risk, and prognosis in COPD patients. Its correlations with traditional inflammatory markers and varying cut-off values across clinical contexts support its role as a valuable tool in managing COPD. Further large-scale, prospective studies are needed to validate its clinical applications and establish standardized NLR thresholds for routine practice.

Keywords: Neutrophil-to-Lymphocyte Ratio, Chronic Obstructive Pulmonary Disease, Acute Exacerbations, Systemic Inflammation, Prognostic Marker

References

Adeloye, D., Song, P., Zhu, Y., Campbell, H., Sheikh, A., & Rudan, I. (2022). Global, regional, and national prevalence of, and risk factors for, chronic obstructive pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respiratory Medicine, 10(5), 447-458. https://doi.org/10.1016/S2213-2600(21)00511-7

Agusti, A., Calverley, P. M., Celli, B., Coxson, H. O., Edwards, L. D., Lomas, D. A., & Vestbo, J. (2010). Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respiratory Research, 11(1), 1-14. https://doi.org/10.1186/1465-9921-11-122

Burney, P. G., Patel, J., Newson, R., Minelli, C., & Naghavi, M. (2015). Global and regional trends in COPD mortality, 1990-2010. European Respiratory Journal, 45(5), 1239-1247. https://doi.org/10.1183/09031936.00142414

Celli, B. R., Fabbri, L. M., Aaron, S. D., et al. (2021). An updated definition and severity classification of chronic obstructive pulmonary disease exacerbations: the Rome proposal. American Journal of Respiratory and Critical Care Medicine, 204(11), 1251-1258. https://doi.org/10.1164/rccm.202108-1819PP

Halpin, D. M. G., Celli, B. R., Criner, G. J., et al. (2019). The GOLD Summit on chronic obstructive pulmonary disease in low-and middle-income countries. International Journal of Tuberculosis and Lung Disease, 23(11), 1131-1141. https://doi.org/10.5588/ijtld.19.0397

Hurst, J. R., & Siddharthan, T. (2020). Global burden of COPD. In R. Haring, I. Kickbusch, D. Ganten, & M. Moeti (Eds.), Handbook of Global Health (pp. 1-20). Springer. https://doi.org/10.1007/978-3-030-05325-3_25-1

Lozano, R., Naghavi, M., Foreman, K., Lim, S., Shibuya, K., Aboyans, V., & Remuzzi, G. (2012). Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. The Lancet, 380(9859), 2095-2128.

Mannino, D. M., & Buist, A. S. (2007). Global burden of COPD: risk factors, prevalence, and future trends. The Lancet, 370(9589), 765-773. https://doi.org/10.1016/S0140-6736(07)61380-4

Mehra, D., Geraghty, P. M., Hardigan, A. A., & Foronjy, R. (2012). A comparison of the inflammatory and proteolytic effects of dung biomass and cigarette smoke exposure in the lung. PLoS One, 7(12), e52889. https://doi.org/10.1371/journal.pone.0052889

Parker, C. M., Voduc, N., Aaron, S. D., Webb, K. A., & O'Donnell, D. E. (2005). Physiological changes during symptom recovery from moderate exacerbations of COPD. European Respiratory Journal, 26(3), 420-428. https://doi.org/10.1183/09031936.05.00136304

Rycroft, C. E., Heyes, A., Lanza, L., & Becker, K. (2012). Epidemiology of chronic obstructive pulmonary disease: a literature review. International Journal of Chronic Obstructive Pulmonary Disease, 7, 457. https://doi.org/10.2147/COPD.S32330

Vestbo, J., Agusti, A., Wouters, E. F., Bakke, P., Calverley, P. M., Celli, B., & Tal-Singer, R. (2014). Should we view chronic obstructive pulmonary disease differently after ECLIPSE? A clinical perspective from the study team. American Journal of Respiratory and Critical Care Medicine, 189(9), 1022-1030. https://doi.org/10.1164/rccm.201311-2006PP

Vogelmeier, C. F., Criner, G. J., Martinez, F. J., et al. (2017). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2017 Report: GOLD executive summary. American Journal of Respiratory and Critical Care Medicine, 195(5), 557-582. https://doi.org/10.1164/rccm.201701-0218PP

Wedzicha, J. A., & Wilkinson, T. M. (2006). Natural history of COPD exacerbations. European Respiratory Journal, 27(1), 71-77. https://doi.org/10.1183/09031936.06.00024905